ArticlePloS one2025
First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03829969 (A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to evaluate the cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) from the perspective of U.S. healthcare payers.
methodsA 10-year partitioned survival model was developed using survival data from the JUPITER-06 clinical trial (NCT03829969). Costs included only direct medical expenses, and health utility values were derived from published literature. One-way and probabilistic sensitivity analysis were performed to assess the robustness of the model.
resultsToripalimab combined with chemotherapy incurred an incremental cost of $64,483.3 and achieved an incremental effectiveness of 0.53 quality-adjusted life-years (QALY) compared to chemotherapy alone, resulting in an incremental cost-effectiveness ratio (ICER) of $122,771.67 per QALY. This ICER is below the willingness-to-pay threshold in the United States ($150,000). The model results were sensitive to the cost of toripalimab and the utility values of both progression-free and progressed disease states.
conclusionsThe findings indicate that toripalimab combined with chemotherapy as a first-line treatment for advanced ESCC in the United States provides a cost-effective benefit in comparison to chemotherapy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.